Mack, K. A., Jones, C. M., and Ballesteros, M. F., “Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas—United States,” American Journal of Transplantation 17 (2017), 3241-3252.CrossRefGoogle Scholar

World Health Organization, Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence (2009), available at <http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf> (last visited January 26, 2018).+(last+visited+January+26,+2018).>Google Scholar

Nosyk, B., Anglin, M.D., Brissette, S., Kerr, T., Marsh, D.C., Shackman, B.R., Wood, E., and Montaner, J.S., “A Call for Evidence-Based Medical Treatment of Opioid Dependence in the United States and Canada,” Health Affairs 32, no. 8 (2013): 1462-1469, at 1462-1463.CrossRefGoogle Scholar

Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A. Jr., and Gordon, M., “Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders,” New England Journal of Medicine 374 (2016): 1232-1242.CrossRefGoogle Scholar

Mattick, R. P., Ali, R., White, J. M., O’brien, S., Wolk, S., and Danz, C., “Buprenorphine versus Methadone Maintenance Therapy: A Randomized Double-Blind Trial with 405 Opioid-Dependent Patients,” Addiction 98, no. 4 (2003): 441-452. See also B. Mund and K. Stith, “Buprenorphine MAT as an Imperfect Fix,” The Journal of Law, Medicine & Ethics 46, no. 2 (2018): 279-291.CrossRefGoogle Scholar

Mattick, R. P., Kimber, J., Breen, C., and Davoli, M., “Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence,” Cochrane Database System Review 2, no. 2 (2008).Google Scholar

Jones, C. M., Campopiano, M., Baldwin, G., and McCance-Katz, E., “National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment,” American Journal of Public Health 105, no. 8 (2015): e55-e63.CrossRefGoogle Scholar

Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., and Stein, B. D., “Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002–11,” Health Affairs 34, no. 6 (2015): 1028-1034.Google Scholar

Jones, A., Honermann, B., Sharp, A., and Millett, G., “Where Multiple Modes Of Medication-Assisted Treatment Are Available,” Health Affairs Blog, available at <https://www.healthaffairs.org/do/10.1377/hblog20180104.835958/full/> (last visited February 27, 2018).+(last+visited+February+27,+2018).>Google Scholar

Chan, L., Hart, L. G., and Goodman, D. C., “Geographic Access to Health Care for Rural Medicare Beneficiaries,” The Journal of Rural Health 22, no. 2 (2006): 140-146.CrossRefGoogle Scholar

Billi, J. E., Pai, C. W., and Spahlinger, D. A., “The Effect of Distance to Primary Care Physician on Health Care Utilization and Disease Burden,” Health Care Management Review 32, no. 1 (2007): 22-29.CrossRefGoogle Scholar

Reif, S., Golin, C. E., and Smith, S. R., “Barriers to Accessing HIV/AIDS Care in North Carolina: Rural and Urban Differences,” AIDS Care 17, no. 5, (2005): 558-565.CrossRefGoogle Scholar

Sigmon, S.C., “Access to Treatment for Opioid Dependence in Rural America: Challenges and Future Directions,” JAMA Psychiatry 71, no. 4 (2014): 359-360, at 359.CrossRefGoogle Scholar

Id.Google Scholar